Search results
Results From The WOW.Com Content Network
Novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday. The Swiss ...
(Reuters) -Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany's Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...
Novartis shareholders are due to vote on the Sandoz spin-off at an extraordinary general meeting on Sept. 15, with the first day of trading scheduled for Oct 4. (Reporting by Ludwig Burger and ...
Valneva along with Dynavax Technologies [11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, [12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.
Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Novartis AG also held 33.3 percent of the shares of Roche until 2022, however it did not exercise control over Roche. [122] Novartis also has two significant license agreements with Genentech, a Roche subsidiary. [123] One agreement is for Lucentis; [124] the other is for Xolair. [125] [121]: 239
(Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar ...
Japanese encephalitis vaccines first became available in the 1930s. [3] One of them was an inactivated mouse brain-derived vaccine (the Nakayama and/or Beijing-1 strain), made by BIKEN and marketed by Sanofi Pasteur as JE-VAX, until production ceased in 2005.